Conte P - Search Results

1

How the COVID-19 Pandemic Impacted on Integrated Care Pathways for Lung Cancer: The Parallel Experience of a COVID-Spared and a COVID-Dedicated Center.

Pasello G, Menis J, Pilotto S, Frega S, Belluomini L, Pezzuto F, Caliò A, Sepulcri M, Cernusco NLV, Schiavon M, Infante MV, Damin M, Micheletto C, Del Bianco P, Giovannetti R, Bonanno L, Fantoni U, Guarneri V, Calabrese F, Rea F, Milella M, Conte P. Pasello G, et al. Among authors: conte p. Front Oncol. 2021 Jun 28;11:669786. doi: 10.3389/fonc.2021.669786. eCollection 2021. Front Oncol. 2021. PMID: 34262861 Free PMC article.

2

The curability of breast cancer and the treatment of advanced disease.

Guarneri V, Conte PF. Guarneri V, et al. Eur J Nucl Med Mol Imaging. 2004 Jun;31 Suppl 1:S149-61. doi: 10.1007/s00259-004-1538-5. Epub 2004 Apr 24. Eur J Nucl Med Mol Imaging. 2004. PMID: 15107948 Review.

3

Safety of intravenous and oral bisphosphonates and compliance with dosing regimens.

Conte P, Guarneri V. Conte P, et al. Oncologist. 2004;9 Suppl 4:28-37. doi: 10.1634/theoncologist.9-90004-28. Oncologist. 2004. PMID: 15459427 Free article. Review.

4

Predictive value of biologic parameters for primary chemotherapy in operable breast cancer.

Frassoldati A, Maur M, Guarneri V, Nicolini M, Conte PF. Frassoldati A, et al. Clin Breast Cancer. 2005 Oct;6(4):315-24. doi: 10.3816/CBC.2005.n.034. Clin Breast Cancer. 2005. PMID: 16277881 Review.

5

Primary systemic therapy in operable breast cancer: clinical data and biological fall-out.

Maur M, Guarneri V, Frassoldati A, Conte PF. Maur M, et al. Among authors: conte pf. Ann Oncol. 2006 May;17 Suppl 5:v158-64. doi: 10.1093/annonc/mdj973. Ann Oncol. 2006. PMID: 16807447 Free article. Review.

6

Primary systemic therapy for operable breast cancer: a review of clinical trials and perspectives.

Guarneri V, Frassoldati A, Giovannelli S, Borghi F, Conte P. Guarneri V, et al. Among authors: conte p. Cancer Lett. 2007 Apr 18;248(2):175-85. doi: 10.1016/j.canlet.2006.07.001. Epub 2006 Aug 21. Cancer Lett. 2007. PMID: 16919869 Review.

7

Evolving nonendocrine therapeutic options for metastatic breast cancer: how adjuvant chemotherapy influences treatment.

Conte P, Guarneri V, Bengala C. Conte P, et al. Clin Breast Cancer. 2007 Dec;7(11):841-9. doi: 10.3816/CBC.2007.n.048. Clin Breast Cancer. 2007. PMID: 18269773 Review.

8

Metastatic breast cancer: therapeutic options according to molecular subtypes and prior adjuvant therapy.

Guarneri V, Conte P. Guarneri V, et al. Among authors: conte p. Oncologist. 2009 Jul;14(7):645-56. doi: 10.1634/theoncologist.2009-0078. Epub 2009 Jul 16. Oncologist. 2009. PMID: 19608638 Free article. Review.

9

The clinical relevance of endocrine-therapy-induced changes in lipid metabolism in breast cancer patients.

Frassoldati A, Guarneri V, Conte P. Frassoldati A, et al. Among authors: conte p. Cancer Biol Ther. 2009 Aug;8(15):1456-8. doi: 10.4161/cbt.8.15.9186. Epub 2009 Aug 5. Cancer Biol Ther. 2009. PMID: 19617703 No abstract available.

10

Achievements and unmet needs in the management of advanced ovarian cancer.

Guarneri V, Piacentini F, Barbieri E, Conte PF. Guarneri V, et al. Gynecol Oncol. 2010 May;117(2):152-8. doi: 10.1016/j.ygyno.2009.11.033. Epub 2010 Jan 6. Gynecol Oncol. 2010. PMID: 20056266 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

788 results

Search Page

Filters